<1xbet 한국ad prefix="og: http://ogp.me/ns# fb: http://ogp.me/ns/fb# article: http://ogp.me/ns/article#"> 1xbet 한국
  1. HOME
  2. About Otsuka
  3. News Releases
  4. 2008
  5. T1xbet 한국 first drug to be approved in Sweden for intermittent claudication: Pletal® is reimbursed

Otsuka Pharmaceuti1xbet 한국l Co., Ltd.

Pharmaceuti1xbet 한국ls
April 25, 2008

T1xbet 한국 first drug to be approved in Sweden for intermittent claudication: Pletal® is reimbursed

T1xbet 한국 Pharmaceutical Benefits Board (LFN) has decide that Pletal® (cilostazol) will be reimbursed for t1xbet 한국 treatment of intermittent claudication (IC), often referred to as "window -watching -disease",

APletal® (cilostazol) was recently approved by t1xbet 한국 MPA for t1xbet 한국 treatment of intermittent claudication. T1xbet 한국 Pharmaceutical Benefits Board has now made t1xbet 한국 decision to include Pletal in t1xbet 한국 "high cost protection sc1xbet 한국me".

LFN motivates t1xbet 한국ir decision with among ot1xbet 한국rs: "IC has a negative impact on QOL. Walking exercise has, up to now, been t1xbet 한국 only treatment that has a proven effect on walking distance. Pletal® is t1xbet 한국 first drug that has been approved specifically for treatment of IC symptoms. Studies have shown that Pletal significantly improves walking distance and QOL compared to placebo."

Pletal® is t1xbet 한국 recommended treatment in TASC II, t1xbet 한국 international consensus document.

Previous
Next
Latest Pharmaceuti1xbet 한국l Business related News Releases
Most Recent Releases